Cargando…
Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease
BACKGROUND: Vascular risk factors have been associated with differences in cognitive performance in epidemiological studies, but evidence in patients with coronary heart disease is more limited. METHODS AND RESULTS: The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509727/ https://www.ncbi.nlm.nih.gov/pubmed/30897999 http://dx.doi.org/10.1161/JAHA.118.010641 |
_version_ | 1783417301943451648 |
---|---|
author | Stewart, Ralph A. H. Held, Claes Krug‐Gourley, Sue Waterworth, Dawn Stebbins, Amanda Chiswell, Karen Hagstrom, Emil Armstrong, Paul W. Wallentin, Lars White, Harvey |
author_facet | Stewart, Ralph A. H. Held, Claes Krug‐Gourley, Sue Waterworth, Dawn Stebbins, Amanda Chiswell, Karen Hagstrom, Emil Armstrong, Paul W. Wallentin, Lars White, Harvey |
author_sort | Stewart, Ralph A. H. |
collection | PubMed |
description | BACKGROUND: Vascular risk factors have been associated with differences in cognitive performance in epidemiological studies, but evidence in patients with coronary heart disease is more limited. METHODS AND RESULTS: The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization to darapladib, a reversible inhibitor of lipoprotein phospholipase A(2) or placebo was evaluated for 10 634 patients with coronary heart disease from 38 countries in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. The Montreal Cognitive Assessment scores for darapladib and placebo groups were similar (mean±SD, 25.3±3.84 versus 25.4±3.73, respectively; P=0.27) and the adjusted odds ratio (OR) for mild cognitive impairment (Montreal Cognitive Assessment score <26) was 1.00 (95% CI, 0.93–1.09). Mild cognitive impairment was more likely with increasing age (OR, 1.33 [1.27–1.41], +5 years after 65). For other baseline clinical characteristics, the strongest independent predictors of cognitive impairment were education (≤8 years versus college/university, OR, 2.95 [2.60–3.35]; >8 years/trade school versus college/university, OR, 1.38 [1.25–1.52] and geographic grouping). Cardiovascular risk factors independently associated with cognitive impairment were history of stroke (OR, 1.43 [1.20–1.71]); <2.5 hours of moderate or vigorous intensity exercise/week (OR, 1.19 [1.04–1.37]); high‐density lipoprotein cholesterol <1.16 mmol/L (OR, 1.19 [1.04–1.37]); diabetes mellitus requiring treatment (OR, yes versus no: 1.15 [1.05–1.26]); and history of hypertension (OR, 1.12 [1.02–1.23]). CONCLUSIONS: In patients with stable coronary heart disease, cognitive performance was associated with modifiable cardiovascular risk factors, educational level, and global region, but was not influenced by darapladib. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00799903. |
format | Online Article Text |
id | pubmed-6509727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65097272019-05-20 Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease Stewart, Ralph A. H. Held, Claes Krug‐Gourley, Sue Waterworth, Dawn Stebbins, Amanda Chiswell, Karen Hagstrom, Emil Armstrong, Paul W. Wallentin, Lars White, Harvey J Am Heart Assoc Original Research BACKGROUND: Vascular risk factors have been associated with differences in cognitive performance in epidemiological studies, but evidence in patients with coronary heart disease is more limited. METHODS AND RESULTS: The Montreal Cognitive Assessment score obtained 3.2±0.37 years after randomization to darapladib, a reversible inhibitor of lipoprotein phospholipase A(2) or placebo was evaluated for 10 634 patients with coronary heart disease from 38 countries in the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. The Montreal Cognitive Assessment scores for darapladib and placebo groups were similar (mean±SD, 25.3±3.84 versus 25.4±3.73, respectively; P=0.27) and the adjusted odds ratio (OR) for mild cognitive impairment (Montreal Cognitive Assessment score <26) was 1.00 (95% CI, 0.93–1.09). Mild cognitive impairment was more likely with increasing age (OR, 1.33 [1.27–1.41], +5 years after 65). For other baseline clinical characteristics, the strongest independent predictors of cognitive impairment were education (≤8 years versus college/university, OR, 2.95 [2.60–3.35]; >8 years/trade school versus college/university, OR, 1.38 [1.25–1.52] and geographic grouping). Cardiovascular risk factors independently associated with cognitive impairment were history of stroke (OR, 1.43 [1.20–1.71]); <2.5 hours of moderate or vigorous intensity exercise/week (OR, 1.19 [1.04–1.37]); high‐density lipoprotein cholesterol <1.16 mmol/L (OR, 1.19 [1.04–1.37]); diabetes mellitus requiring treatment (OR, yes versus no: 1.15 [1.05–1.26]); and history of hypertension (OR, 1.12 [1.02–1.23]). CONCLUSIONS: In patients with stable coronary heart disease, cognitive performance was associated with modifiable cardiovascular risk factors, educational level, and global region, but was not influenced by darapladib. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00799903. John Wiley and Sons Inc. 2019-03-22 /pmc/articles/PMC6509727/ /pubmed/30897999 http://dx.doi.org/10.1161/JAHA.118.010641 Text en © 2019 The Authors and GlaxoSmithKline. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Stewart, Ralph A. H. Held, Claes Krug‐Gourley, Sue Waterworth, Dawn Stebbins, Amanda Chiswell, Karen Hagstrom, Emil Armstrong, Paul W. Wallentin, Lars White, Harvey Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease |
title | Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease |
title_full | Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease |
title_fullStr | Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease |
title_full_unstemmed | Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease |
title_short | Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease |
title_sort | cardiovascular and lifestyle risk factors and cognitive function in patients with stable coronary heart disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509727/ https://www.ncbi.nlm.nih.gov/pubmed/30897999 http://dx.doi.org/10.1161/JAHA.118.010641 |
work_keys_str_mv | AT stewartralphah cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT heldclaes cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT kruggourleysue cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT waterworthdawn cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT stebbinsamanda cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT chiswellkaren cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT hagstromemil cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT armstrongpaulw cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT wallentinlars cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease AT whiteharvey cardiovascularandlifestyleriskfactorsandcognitivefunctioninpatientswithstablecoronaryheartdisease |